[Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children].
Neutropenia is the most often side effect during antineoplastic treatment. In this article current recommendations for clinical applications of granulocyte and granulocyto-macrophage hematopoietic factors and possibility of protection of neutropenia, and its serious complications in pediatric oncology are presented.
Balwierz
Walentyna
W
Klinika Onkologii i Hematologii, Polsko-Amerykańskiego Instytutu Pediatrii, Collegium Medicum, Uniwersytetu Jagiellohrskiego w Krakowie. balwierz@mp.pl
Moryl-Bujakowska
Angelina
A
Balwierz
Adriana
A
Pawińska
Katarzyna
K
D000380:Agranulocytosis / Q000139:chemically induced / Q000517:prevention & control; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced* / Q000517:prevention & control; D011994:Recombinant Proteins / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C082430:molgramostim; D000069585:Filgrastim